Get the Stockscreener App
2.59
1.17%
0.03
After Hours:
2.61
0.02
+0.77%
Savara Inc stock is traded at $2.59, with a volume of 834.83K.
It is up +1.17% in the last 24 hours and up +13.60% over the past month.
Savara Inc is a biopharmaceutical company. It is focused on rare respiratory diseases. The company's program, molgramostim nebulizer solution (molgramostim), is an inhaled granulocyte-macrophage colony-stimulating factor in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). It has one segment specialty pharmaceuticals within the respiratory system.
See More
Previous Close:
$2.56
Open:
$2.52
24h Volume:
834.83K
Relative Volume:
0.56
Market Cap:
$447.65M
Revenue:
-
Net Income/Loss:
$-54.70M
P/E Ratio:
-7.8485
EPS:
-0.33
Net Cash Flow:
$-51.36M
1W Performance:
+1.57%
1M Performance:
+13.60%
6M Performance:
-4.07%
1Y Performance:
-43.70%
1-Day Range:
$2.52
$2.61
1-Week Range:
$2.50
$2.84
52-Week Range:
$1.89
$4.74
Savara Inc Stock (SVRA) Company Profile
Name
Savara Inc
Sector
Industry
Phone
51285113796
Address
6836 BEE CAVE ROAD, AUSTIN, TX
Compare SVRA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SVRA
Savara Inc
|
2.59 | 442.46M | 0 | -54.70M | -51.36M | -0.33 |
|
VRTX
Vertex Pharmaceuticals Inc
|
456.87 | 120.48B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
545.46 | 59.88B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
392.24 | 44.31B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
670.33 | 36.65B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
301.13 | 32.46B | 3.81B | -644.79M | -669.77M | -6.24 |
Savara Inc Stock (SVRA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-29-25 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Dec-20-24 | Initiated | Wells Fargo | Overweight |
| Nov-13-24 | Downgrade | Evercore ISI | Outperform → In-line |
| Feb-15-24 | Initiated | JMP Securities | Mkt Outperform |
| Nov-07-23 | Initiated | Guggenheim | Buy |
| May-16-23 | Upgrade | Jefferies | Hold → Buy |
| Mar-31-23 | Downgrade | Jefferies | Buy → Hold |
| Mar-16-21 | Initiated | Piper Sandler | Overweight |
| Mar-15-21 | Initiated | Oppenheimer | Outperform |
| Jun-13-19 | Reiterated | H.C. Wainwright | Buy |
| Jun-13-19 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Jun-13-19 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| Aug-13-18 | Resumed | ROTH Capital | Neutral |
| Jan-03-18 | Initiated | Ladenburg Thalmann | Buy |
| Sep-27-17 | Resumed | ROTH Capital | Buy |
| Sep-22-17 | Initiated | Jefferies | Buy |
| Sep-11-17 | Initiated | JMP Securities | Mkt Outperform |
View All
Savara Inc Stock (SVRA) Latest News
Oppenheimer Assumes Coverage of Savara (SVRA) With an Outperform Rating - Insider Monkey
14 Best Biotech Penny Stocks to Buy Right Now - Insider Monkey
Is Savara Inc. a growth stock or a value stockWealth Building Review That Work - jammulinksnews.com
What makes Savara Inc. stock price move sharplySecure Return Focused Investment Plan Released - beatles.ru
Heatmap Data Shows High Activity in Savara Inc. SectorAI Screening for Swing Trade Picks Finds Momentum - metal.it
Recovery Setup Building in Savara Inc. Experts SayEntry Plan for Oversold Reversal Stocks Released - metal.it
What technical models suggest about Savara Inc.’s comebackStock Portfolio Risk and Return Analysis - Newser
Using flow based indicators on Savara Inc.Free Community Entry Consensus Trade Ideas - Newser
Real time pattern detection on Savara Inc. stockFree Buy Low Sell High Stock Watch - Newser
Why Savara Inc. stock attracts strong analyst attentionStock Portfolio Allocation Guidance for Volatile Markets - beatles.ru
What is the risk reward ratio of investing in Savara Inc. stockBuild wealth faster with expert stock selection - jammulinksnews.com
What are analysts’ price targets for Savara Inc. in the next 12 monthsHigh-profit stock alerts - jammulinksnews.com
Will Savara Inc. outperform the marketFree Growth Based Investment Plan Guidance - Newser
Why is Savara Inc. stock attracting strong analyst attentionRetirement Planning Forecasts Backed By Experts - jammulinksnews.com
Using flow based indicators on Savara Inc. Trade Safety Matrix for Conservative Traders - Newser
Heatmap analysis for Savara Inc. and competitors Downside Control Plan With Support Analysis - Newser
What recovery options are there for Savara Inc. Free Market Surge Signal for Swing Traders - Newser
What are the technical indicators suggesting about Savara Inc.Market Forecast Planner With Proven Results - jammulinksnews.com
Is Savara Inc. stock overvalued or undervaluedPre Market Review For Consistent Profits - jammulinksnews.com
What is Savara Inc. company’s growth strategyFree Stock Market Return Analysis - jammulinksnews.com
What are Savara Inc. company’s key revenue driversAccess high-yield investment alerts now - jammulinksnews.com
Key External Factors That Drive Savara Inc. Stock Price MovementsFree Access to Stock Community - Newser
Great Week for Savara Inc. (NASDAQ:SVRA) Institutional Investors After Losing 42% Over the Previous Year - 富途牛牛
Savara Inc. Stock Analysis and ForecastUnprecedented profits - PrintWeekIndia
What analysts say about Savara Inc. stockExtraordinary earning power - Autocar Professional
What drives Savara Inc. stock priceRobust investment performance - PrintWeekIndia
Savara Inc. Grants Inducement Awards to New Employees with Stock Options & RSUs - MSN
Analysts Set Savara Inc. (NASDAQ:SVRA) PT at $5.60 - Defense World
Savara's Path to Overcoming the FDA RTF for MOLBREEVI and Reclaiming aPAP Market Leadership - AInvest
Savara: Repairing The Molbreevi aPAP Opportunity After RTF (NASDAQ:SVRA) - Seeking Alpha
Is Savara Inc. a good long term investmentTurbocharged investment results - jammulinksnews.com
How Savara Inc. stock reacts to Fed policy changesTrend Following Trades - Newser
Savara Inc Stock (SVRA) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.43%
2.00%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):